Key Highlights
- Kathleen Sereda Glaub appointed as Chief Executive Officer of CuraSen Therapeutics.
- Dr. Anthony Ford takes on the role of President and Chief Scientific Officer.
- Clinical program updates include CuraAX for neurogenic orthostatic hypotension, CuraCN for major depressive disorder, and CuraXN for Alzheimer’s.
- CuraSen plans to submit an IND application for CuraAX in 2024.
- CuraSen’s drug candidates aim to restore adrenergic function, potentially improving cognition and mood.
Source: Business Wire
Notable Quotes
- “CuraSen will benefit from the collective and complementary executive experience of both Ms. Glaub and Dr. Ford, both co-founders of the company.” — Patrick Enright, Board Chair at Longitude Capital
- “Our adrenergic target mechanisms are already validated by approved drugs… we believe there is a unique opportunity to address depression in these patients with CuraCN.” — Kathleen Sereda Glaub, CEO at CuraSen Therapeutics
SoHC's Take
The appointment of Kathleen Sereda Glaub as CEO brings a wealth of strategic and leadership experience, positioning CuraSen for success in advancing its clinical programs. The company’s focus on restoring adrenergic function addresses a critical need in neurodegenerative and psychiatric conditions. With the upcoming IND application for CuraAX and compelling Phase 2 data for CuraCN and CuraXN, CuraSen is well-poised to make significant strides in treating conditions like nOH, major depressive disorder, and Alzheimer’s disease. This executive change, coupled with the promising clinical pipeline, makes CuraSen a key player to watch in the biopharmaceutical space.
